Stereotaxis, Inc. (STXS)
| Market Cap | 181.31M |
| Revenue (ttm) | 32.38M |
| Net Income (ttm) | -22.91M |
| Shares Out | 97.48M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 233,865 |
| Open | 1.940 |
| Previous Close | 1.930 |
| Day's Range | 1.845 - 1.945 |
| 52-Week Range | 1.740 - 3.590 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+115.05%) |
| Earnings Date | May 12, 2026 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Na... [Read more]
Financial Performance
In 2025, Stereotaxis's revenue was $32.38 million, an increase of 20.28% compared to the previous year's $26.92 million. Losses were -$22.91 million, -9.62% less than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 115.05% from the latest price.
News
Stereotaxis Announces First MAGiC Procedures in the United States
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first pat...
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...
Stereotaxis Transcript: M&A announcement
The acquisition of Robocath brings complementary robotic technology, accelerating the strategy to lead in endovascular procedures. The deal includes up to $45 million in payments, targets a $20–30 billion market, and expects break-even by year three post-close.
Stereotaxis Announces Definitive Agreement to Acquire Robocath
ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today annou...
Stereotaxis Announces FDA Clearance and Launch of Synchrony System
ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has r...
Stereotaxis Earnings Call Transcript: Q4 2025
Delivered 36% Q4 revenue growth and launched new robotic and catheter products after key regulatory approvals. Manufacturing ramp and transition to proprietary catheters are underway, with double-digit revenue growth and margin expansion expected in 2026.
Stereotaxis Reports 2025 Full Year Financial Results
ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program
ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of ...
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter
ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U....
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the compa...
Stereotaxis Earnings Call Transcript: Q3 2025
Stereotaxis Reports 2025 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...
GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance
ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it receiv...
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025
ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs
ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE...
Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias
ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and Car...
Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System
ST. LOUIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful fi...
First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successfu...
Stereotaxis to Present at Upcoming Investor Conferences
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi...
Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025
ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology...
Stereotaxis Earnings Call Transcript: Q2 2025
Q2 2025 revenue nearly doubled year-over-year, driven by new product launches and regulatory milestones. MAGIC and MAGIC Sweep catheters are expanding recurring revenue, with guidance reaffirmed for double-digit growth and a strengthened cash position post-equity raise.
Stereotaxis Reports 2025 Second Quarter Financial Results
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...
Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter
ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has re...
Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...